eculizumab biosimilar (Harvest Moon Pharmaceuticals)

N/A

Report date: 2025/01/26 18:59:48

Base Information

Drug Nameeculizumab biosimilar (Harvest Moon Pharmaceuticals)
Drug Alias NameHMP-2019
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement C5 inhibitors
TargetsComplement C5
Therapy Area/IndicationsThrombotic MicroangiopathiesHemoglobinuria, ParoxysmalHemolytic-Uremic Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHarvest Moon
China Registration ClassN/A

Develop Information

Active CompaniesHarvest Moon
Inactive CompaniesN/A
Active IndicationsThrombotic MicroangiopathiesHemoglobinuria, ParoxysmalHemolytic-Uremic Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A